LLY Stock: Unusual Options Activity Flags Long-Dated Bearish Bets Even as Eli Lilly Holds Above $1,000

By TrendSpider Editor

LLY market update based on latest unusual_options data.

LLY Stock: Unusual Options Activity Flags Long-Dated Bearish Bets Even as Eli Lilly Holds Above $1,000

Eli Lilly and Company is seeing a cluster of unusual options activity, with four contracts totaling $326,460 in premium drawing attention across both calls and puts. LLY shares are trading at $1,002.09, down 0.50% on the session, sitting well off the 52-week high of $1,133.95 but holding comfortably above the 52-week low of $623.79. The options flow skews notably bearish, with three of the four flagged contracts being in-the-money puts on strikes above the current price.

Key Drivers of the LLY Stock Move

• Main Catalyst: Four unusual options contracts were detected on LLY, generating $326,460 in total premium. Activity includes a long-dated CALL at the $1,060 strike expiring March 19, 2027, and three ITM PUT contracts at strikes of $1,080 and $1,090, all expiring December 15, 2028. Each contract carried an open interest change of 1,000%, signaling fresh positioning rather than existing flow.
• Bull Case: The single CALL contract at the $1,060 strike, expiring March 19, 2027, generated $145,500 in premium alone, representing the largest single-contract premium in the batch. A bet at $1,060 implies the market sees a viable path back above that level, which would represent a roughly 5.8% move from the current price of $1,002.09.
• Bear Case: Three of the four flagged contracts are in-the-money puts at strikes of $1,080 and $1,090, all targeting December 2028 expiration. These positions carry a combined premium of $180,960 and sit above the current stock price, meaning they are already in the money. The concentration of ITM long-dated put activity suggests at least some participants are hedging against, or outright betting on, sustained downside from current levels.

The forward setup for LLY is nuanced. The stock has recovered meaningfully from its 52-week low of $623.79 but remains approximately 11.6% below its 52-week high of $1,133.95, leaving it in a recovery phase with unresolved overhead supply. The divergence between a near-term bullish call and a cluster of long-dated bearish puts suggests the options market is split on where LLY heads over the next one to three years. Eli Lilly remains one of the most closely watched names in large-cap pharma given its GLP-1 franchise anchored by Mounjaro and Zepbound, and any updates on supply capacity, competitive dynamics with Novo Nordisk, or pipeline readouts could be decisive catalysts in either direction.

LLY Unusual Options Activity

• CALL | Strike: $1,060 | Expiry: March 19, 2027 | Volume: 10 | Open Interest Change: 1,000% | Status: OTM | Premium: $145,500
• PUT | Strike: $1,080 | Expiry: December 15, 2028 | Volume: 1 | Open Interest Change: 1,000% | Status: ITM | Premium: $25,680
• PUT | Strike: $1,080 | Expiry: December 15, 2028 | Volume: 4 | Open Interest Change: 1,000% | Status: ITM | Premium: $102,700
• PUT | Strike: $1,090 | Expiry: December 15, 2028 | Volume: 2 | Open Interest Change: 1,000% | Status: ITM | Premium: $52,580

Total premium across all four contracts came in at $326,460. The put-side contracts at $1,080 and $1,090 are in the money relative to the current price of $1,002.09, underscoring the directional weight of the bearish positioning. All contracts registered a 1,000% surge in open interest, confirming these are new positions being established rather than existing hedges being rolled or closed.

LLY Seasonality

Historically, large-cap pharmaceutical names including Eli Lilly have tended to see increased institutional options activity in the late winter and early spring period as investors position ahead of mid-year clinical readouts and conference season. The long-dated nature of the December 2028 puts suggests these are not short-term tactical trades but rather strategic positions being established well in advance of anticipated catalysts or macro shifts in the healthcare sector.

LLY Relative Performance

LLY is down 0.50% on the session at $1,002.09, a modest move in isolation but worth monitoring in the context of its recovery from the 52-week low of $623.79. The stock has retraced a substantial portion of that drawdown from the 52-week high of $1,133.95, though it has not yet reclaimed that peak. Relative to the broader large-cap pharmaceutical peer group, LLY's four-digit share price and continued proximity to the $1,000 psychological level keep it in focus as a bellwether for the GLP-1 and obesity drug investment theme.